SDS22 is an ancient protein phosphatase 1 (PP1) regulatory protein that associates with PP1 at kinetochores and regulates PP1-mediated dephosphorylation of Aurora B kinase. Here, the crystal structure of human SDS22 in a P212121 crystal form reveals that this leucine-rich repeat protein is highly curved, resulting in distinct surfaces that are likely to be important for PP1 binding.
Keywords: SDS22, protein phosphatase 1, LRR protein, PP1 regulator
Abstract
Protein phosphatase 1 (PP1) dephosphorylates hundreds of key biological targets by associating with nearly 200 regulatory proteins to form highly specific holoenzymes. The vast majority of regulators are intrinsically disordered proteins (IDPs) and bind PP1 via short linear motifs within their intrinsically disordered regions. One of the most ancient PP1 regulators is SDS22, a protein that is conserved from yeast to mammals. Sequence analysis of SDS22 revealed that it is a leucine-rich repeat (LRR) protein, suggesting that SDS22, unlike nearly every other known PP1 regulator, is not an IDP but instead is fully structured. Here, the 2.9 Å resolution crystal structure of human SDS22 in space group P212121 is reported. SDS22 adopts an LRR fold with the horseshoe-like curvature typical for this family of proteins. The structure results in surfaces with distinct chemical characteristics that are likely to be critical for PP1 binding.
1. Introduction
Protein phosphatase 1 (PP1), a single-domain protein that is exceptionally well conserved from fungi to humans, is one of the most widely expressed and abundant serine/threonine phosphatases (Brautigan & Shenolikar, 2018 ▸). As a consequence, PP1 regulates a diverse set of processes, including carbohydrate metabolism, protein synthesis and cell division, among many others (Cohen, 2002 ▸). Although free PP1 has no specificity, in cells PP1 dephosphorylates numerous targets with exquisite specificity. This is achieved via its interaction with ∼200 distinct regulatory proteins, including inhibitory proteins that keep PP1 in an inactive state (such as inhibitor-2) and targeting proteins that form highly specific holoenzymes (such as spinophilin, GADD34, KNL1 and RepoMan) (Peti et al., 2013 ▸).
Multiple biochemical and structural studies have revealed that the vast majority of these regulatory proteins bind PP1 via short linear motifs (SLiMs). These SLiMs are between two and eight residues in length, are found within intrinsically disordered regions (IDRs) of the regulators and function to mediate protein–protein interactions. While PP1-specific SLiMs are unstructured in solution, they become ordered when bound to PP1 (Bajaj et al., 2018 ▸; Choy et al., 2014 ▸, 2015 ▸; Ragusa et al., 2010 ▸). The first SLiM to be identified in regulators of PP1 was RVxF, where x represents any amino acid. Subsequent structural studies revealed that this SLiM binds to a deep hydrophobic pocket on PP1 that is ∼20 Å from the catalytic site (Egloff et al., 1997 ▸). Since then, additional PP1-specific SLiMs have been identified, including the SILK (Hurley et al., 2007 ▸), ΦΦ (O’Connell et al., 2012 ▸), Arg (Choy et al., 2014 ▸) and KiR (Kumar et al., 2016 ▸) SLiMs, which each bind to PP1 at distinct pockets.
SDS22 is a regulator of PP1 that is conserved from yeast to humans (Fig. 1 ▸; Brautigan & Shenolikar, 2018 ▸). Upon its discovery nearly 30 years ago, an analysis of the SDS22 sequence revealed that it consists almost entirely of folded leucine-rich repeats (LRRs; Ohkura & Yanagida, 1991 ▸). This makes SDS22 unusual among PP1 regulators in that SDS22 is not an intrinsically disordered protein (IDP) but instead is likely to bind PP1 via its folded domain. Consistent with this hypothesis, SDS22 does not contain the RVxF SLiM that is present in nearly 85% of all known PP1 regulators. Further, in 2002, yeast two-hybrid studies showed that mutations in the folded domain of SDS22 disrupt PP1 binding (Ceulemans et al., 2002 ▸). SDS22 has also been shown to form a trimeric complex with both PP1 and a second PP1 regulator, inhibitor-3 (I-3; Pedelini et al., 2007 ▸). More recently, SDS22 has been shown to regulate PP1-mediated dephosphorylation of Aurora B kinase (Eiteneuer et al., 2014 ▸) and promote the folding of PP1 into its active conformation upon protein synthesis (Weith et al., 2018 ▸). Here, we describe the crystal structure of human SDS22 in a P212121 crystal form and show how the regular LRRs in SDS22 result in biophysically distinct surfaces; these surfaces, coupled with the crystal contacts that SDS22 makes with itself in the asymmetric unit, reveal new insights into the likely mechanism by which SDS22 complexes with PP1.
2. Materials and methods
2.1. Macromolecule production
2.1.1. Plasmid construction
The SDS22 (56–360; UniProt ID Q15435) gene was cloned into a modified pcDNA3.4 vector (pcDNA3.4_K_RP1B). The pcDNA3.4_K_RP1B vector contains a Kozak consensus sequence, an N-terminal 6×His tag, a TEV cleavage site and a multiple cloning site (the latter elements are derived from the Escherichia coli RP1B expression vector; Peti & Page, 2007 ▸) following the pcDNA3.4 human cytomegalovirus (CMV) promoter. This plasmid was amplified and purified using the PureLink HiPure Plasmid Maxiprep Kit (ThermoFisher).
2.1.2. Protein expression
The recombinant protein was expressed in Expi293F cells (ThermoFisher) at a ratio of 1.0 µg DNA per millilitre of final transfection-culture volume. Transfections were performed using 600 ml in 2 l baffled flasks according to the manufacturer’s protocol. The Expi293F cells were cultured in Gibco Expi293 Expression Medium (ThermoFisher) in a humidified incubator at 37°C and 6.5% CO2 with shaking at 125 rev min−1. On the day of transfection, the Expi293F cell density was between 3 and 5 × 106 cells ml−1. Prior to transfection, the Expi293F cells were seeded at 2.9 × 106 cells ml−1 in 85% of the final transfection volume. SDS22 (56–360) DNA was mixed with Opti-MEM Reduced Serum Medium (ThermoFisher); in a separate tube, Expifectamine reagent (ThermoFisher) was mixed with Opti-MEM medium. These mixtures were incubated separately for 5 min, after which the DNA and Expifectamine mixtures were combined and incubated for an additional 20 min. The final transfection mixture was then added to the cells. Enhancer 1 and Enhancer 2 were added to the cells 18–20 h post-transfection. After an additional 24–28 h, the cells were harvested and the pellet was stored at −80°C.
2.1.3. Protein purification
The cell pellet was resuspended in ice-cold lysis buffer (25 mM Tris pH 8.0, 0.5 M NaCl, 5 mM imidazole, 0.1% Triton X-100) with one cOmplete Mini EDTA-free protease-inhibitor cocktail tablet (Sigma). The resuspended cells were lysed using an Avestin Emulsiflex 3C high-pressure homogenizer at 10.3 MPa. The cell lysate was clarified by centrifugation at 40 000g for 45 min and the resulting supernatant was filtered using a 0.22 µm syringe filter (Millipore). The filtered supernatant was then loaded onto a HisTrap FF column (GE Healthcare) pre-equilibrated with buffer A (25 mM Tris pH 8.0, 500 mM NaCl, 5 mM imidazole). The column was washed with buffer A until the baseline was reached, followed by a wash with 8% buffer B (25 mM Tris pH 8.0, 500 mM NaCl, 250 mM imidazole); after this, the protein was eluted using a linear gradient of 8–60% buffer B. The fractions containing SDS22 were pooled and the His6 tag was cleaved using tobacco etch viral protease (overnight incubation at 4°C in SDS22 buffer: 20 mM Tris pH 8.0, 500 mM NaCl, 0.5 mM TCEP, 1 mM MnCl2). The cleaved His6 tag and TEV were removed using a second Ni–NTA column. The SDS22 protein was then combined with PP1α7–300 (Choy et al., 2014 ▸) at various molar ratios and incubated on ice for 60 min, after which the complex was purified using size-exclusion chromatography (Superdex S75 column equilibrated in SDS22 buffer; Fig. 2 ▸). The purity of the complex was quantified using SDS–PAGE. The complex was concentrated to 10 mg ml−1 for crystallization trials. Macromolecule-production information is summarized in Table 1 ▸.
Table 1. Macromolecule-production information.
Source organism | Homo sapiens |
Expression vector | pcDNA3.4_K_RP1B |
Expression host | HEK293F |
UniProt ID | Q15435 |
Complete amino-acid sequence of the construct produced† | GHMGSEEDPEEEHELPVDMETINLDRDAEDVDLNHYRIGKIEGFEVLKKVKTLCLRQNLIKCIENLEELQSLRELDLYDNQIKKIENLEALTELEILDISFNLLRNIEGVDKLTRLKKLFLVNNKISKIENLSNLHQLQMLELGSNRIRAIENIDTLTNLESLFLGKNKITKLQNLDALTNLTVLSMQSNRLTKIEGLQNLVNLRELYLSHNGIEVIEGLENNNKLTMLDIASNRIKKIENISHLTELQEFWMNDNLLESWSDLDELKGARSLETVYLERNPLQKDPQYRRKVMLALPSVRQIDATFVRF |
Residues not modeled owing to a lack of electron density are shown in italics.
2.2. Crystallization
Initial crystallization trials were performed using Intelli-Plates 96-3 (Art Robbins) and different commercial sparse-matrix screens (JCSG, BCS Eco, LMB and ProPlex) at room temperature and 4°C. The crystals used for data collection and structure determination were obtained at room temperature in hanging-drop Linbro trays (pH adjusted to 7.8; the conditions are described in Table 2 ▸). Crystals typically formed within three days. SDS–PAGE of washed crystals showed that they consisted exclusively of SDS22 (subsequent limited digestion studies of the in vitro reconstituted SDS22–PP1 complex showed that complex formation renders PP1 unusually susceptible to proteolysis; why this occurs is under active investigation). The crystals were harvested, cryoprotected using mother liquor supplemented with 30%(v/v) glycerol and immediately flash-cooled in liquid nitrogen.
Table 2. Crystallization.
Method | Hanging-drop vapor diffusion |
Plate type | 24-well Linbro plate |
Temperature (K) | 298 |
Protein concentration (mg ml−1) | 10 |
Buffer composition of protein solution | 20 mM Tris pH 8.0, 500 mM NaCl, 0.5 mM TCEP, 1 mM MnCl2 |
Composition of reservoir solution | 0.1 M HEPES pH 7.8, 0.2 M ammonium sulfate, 0.01 M cadmium chloride hemi(pentahydrate), 25%(v/v) PEG Smear Medium |
Volume and ratio of drop | 3 µl; 1:2 condition:protein |
Volume of reservoir (ml) | 0.5 |
2.3. Data collection and processing
Crystallographic data were collected on beamline 12-2 (wavelength of 0.98 Å) at the Stanford Synchrotron Radiation Lightsource (SSRL) and were processed using autoXDS (XDS, AIMLESS and TRUNCATE; Table 3 ▸) to a resolution of 2.9 Å (Gonzolez & Tsai, 2010 ▸; Kabsch, 2010 ▸; Evans & Murshudov, 2013 ▸).
Table 3. Data collection and processing.
Diffraction source | Beamline 12-2, SSRL |
Wavelength (Å) | 0.97946 |
Temperature (K) | 100 |
Detector | PILATUS 6M, Dectris |
Crystal-to-detector distance (mm) | 520.5 |
Rotation range per image (°) | 0.15 |
Total rotation range (°) | 200 |
Exposure time per image (s) | 1 |
Space group | P212121 |
a, b, c (Å) | 75.1, 76.5, 128.3 |
α, β, γ (°) | 90, 90, 90 |
Mosaicity (°) | 0.1 |
Resolution range (Å) | 38.27–2.90 (3.08–2.90) |
Total No. of reflections | 124116 (19788) |
No. of unique reflections | 16949 (2677) |
Completeness (%) | 99.6 (99.5) |
Multiplicity | 7.3 (7.4) |
〈I/σ(I)〉 | 10.6 (2.2) |
R meas | 0.215 (2.86) |
CC1/2 | 0.965 (0.423) |
Overall B factor from Wilson plot (Å2) | 72 |
2.4. Structure solution and refinement
The structure was determined using molecular replacement (with Phaser as implemented in PHENIX; Adams et al., 2010 ▸; McCoy et al., 2007 ▸). PDB entry 4awa (Dall & Brandstetter, 2013 ▸) was used as a search model (the N- and C-terminal caps were deleted and the number of central LRRs was extended from eight to 11; 22% identity; selected using FFAS; Xu et al., 2014 ▸), resulting in a translation Z-score of 16.4. AutoBuild as implemented in PHENIX was used to improve the initial molecular-replacement model. The model was completed using multiple cycles of building and refinement using Coot and phenix.refine, respectively (Fig. 3 ▸). The data and coordinates were deposited in the PDB with PDB entry 6mky. Structure-solution and refinement statistics are given in Table 4 ▸.
Table 4. Structure solution and refinement.
Resolution range (Å) | 37.6–2.90 (2.98–2.90) |
Completeness (%) | 99.2 (96.0) |
No. of reflections, working set | 16841 |
No. of reflections, test set | 1738 |
Final R cryst | 0.241 (0.317) |
Final R free | 0.272 (0.368) |
No. of non-H atoms | |
Protein | 4234 |
Ion (sulfate) | 50 |
Water | 17 |
Total | 4301 |
R.m.s. deviations | |
Bonds (Å) | 0.002 |
Angles (°) | 0.458 |
Average B factors (Å2) | |
Protein | 76 |
Ion (sulfate) | 91 |
Water | 63 |
Ramachandran plot† | |
Most favored (%) | 92.4 |
Allowed (%) | 7.6 |
Most favored/allowed definitions as determined using MolProbity (Williams et al., 2018 ▸).
2.5. Sequence alignments
HMMER (Finn et al., 2011 ▸) was used to identify and align SDS22 sequences from 39 distinct species. The alignment was then provided to ConSurf (Ashkenazy et al., 2016 ▸) in order to calculate conservation scores for each amino acid and bin them according to their conservation score. The residues in each bin are given a different color, ranging from dark pink (conserved) to teal (variable), and are plotted as a molecular surface using the SDS22 coordinates in PyMOL (Schrödinger; http://www.pymol.org).
3. Results and discussion
We determined the structure of SDS22 residues 100–360, which constitute LRR2–LRR12 and the C-terminal cap [residues 1–88 of SDS22 were previously shown to be dispensable for PP1 binding (Ceulemans et al., 2002 ▸), which is consistent with their lack of conservation throughout evolution (Fig. 1 ▸)], in space group P212121. SDS22 adopts the horseshoe fold characteristic of LRR proteins, resulting in both a concave and a convex surface (Fig. 4 ▸ a); the short parallel β-strands in each LRR define the concave surface of SDS22. The overall curvature of SDS22 is about 180° and spans a distance of ∼36 Å. Thirty-nine SDS22 sequences from a diversity of organisms were used to identify the highly conserved versus variable residues in SDS22 sequences (Fig. 4 ▸ b). As expected, the hydrophobic residues that stabilize the LRR fold are conserved, as are the asparagine residues that form the ‘Asn ridge’ (Fig. 4 ▸ c). These features are key elements of all LRR proteins and function to define the horseshoe-type fold that is characteristic of this family of proteins (for example, the Asn ridge connects neighboring repeats via side chain-to-main chain hydrogen bonds; Rämisch et al., 2014 ▸). However, about 20 residues that are not part of the LRR fold are also exceptionally conserved in all 39 sequences. Notably, these are located on the concave surface of SDS22 (Fig. 4 ▸ c, upper left); all other residues are considerably more variable.
Mapping the electrostatic surface onto the surface of SDS22 reveals that the basic arginine/lysine and the acidic aspartic/glutamic acid residues cluster into distinct patches on the surface of SDS22. Both the concave and convex surfaces are characterized by acidic patches (Fig. 5 ▸ a). In contrast, the ‘top’ and ‘bottom’ surfaces of SDS22 are characterized by basic patches (Fig. 5 ▸ b). No distinctive hydrophobic patches that may be indicative of a hydrophobic binding pocket are observed.
SDS22 binds PP1 and functions to both promote the folding of PP1 into its active conformation upon protein synthesis (Weith et al., 2018 ▸) and regulate the PP1-mediated dephosphorylation of Aurora B kinase (Eiteneuer et al., 2014 ▸). An analysis of the asymmetric unit in the P212121 crystal form provides key additional insights into how SDS22 is likely to associate with PP1. Firstly, as described above, 20 of the most conserved residues in SDS22 are not part of the LRR hydrophobic core. Rather, they are clustered in a single location: the concave surface of SDS22 (Fig. 6 ▸ a). This suggests that they are critical for mediating protein–protein interactions. Because PP1 is also highly conserved throughout evolution, these data suggest that PP1 binds to the concave surface of SDS22. This is consistent with the observation that in most LRR–ligand complexes for which structures have been determined the ligand-binding site is located on the concave surface of the LRR (Bell et al., 2003 ▸). Secondly, because two molecules of SDS22 are present in the crystallographic asymmetric unit (Fig. 6 ▸ b), how they interact with one another provides insights into the potential mechanisms used by PP1 to bind SDS22. The two SDS22 molecules in the asymmetric unit are essentially identical, superimposing with a root-mean-square deviation of 0.46 Å. In the crystal, the first molecule of SDS22 binds to the second via its concave surface, burying more than 1800 Å2 of solvent-accessible surface area (BSA; Tina et al., 2007 ▸). Although SDS22 is a monomer in solution, as determined by gel-filtration chromatography, this BSA value is in the range observed for bona fide intermolecular interactions. Because PP1 is globular, with dimensions similar to the concave curvature of SDS22, and because the concave surface is the location of the most highly conserved residues in SDS22, it is most likely that PP1 also binds to the concave surface of SDS22.
The intermolecular interactions between the two SDS22 molecules in the asymmetric unit are exclusively electrostatic/polar. The residues from the concave surface of SDS22 that mediate these interactions are the most highly conserved residues (Fig. 6 ▸ c; Arg106, Asp129, Asp148, Glu192 and Tyr327). They form both salt bridges and hydrogen bonds with residues from the second molecule of SDS22 that include residues from the basic ridge (Arg155, Arg197, Arg199 and Lys219). Because eight of the 20 most highly conserved residues are charged, it is highly likely that charge–charge interactions play a role in PP1 binding, a hypothesis that is consistent with the interface observed between the two molecules of SDS22. Although achieving a full understanding of how SDS22 binds PP1 and how this complex facilitates the interaction of PP1 with other PP1-specific regulators will require additional structural and biophysical characterization, the structure described here represents a key step in achieving this goal.
Supplementary Material
Acknowledgments
This research used beamline 12.2 at the Stanford Synchrotron Radiation Lightsource. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory is supported by the US Department of Energy, Office of Science and Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393).
Funding Statement
This work was funded by National Institute of General Medical Sciences grant R01GM098482 to Rebecca Page. National Institute of Neurological Disorders and Stroke grant R01NS056128 to Wolfgang Peti.
References
- Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C. & Zwart, P. H. (2010). Acta Cryst. D66, 213–221. [DOI] [PMC free article] [PubMed]
- Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T. & Ben-Tal, N. (2016). Nucleic Acids Res. 44, W344–W350. [DOI] [PMC free article] [PubMed]
- Bajaj, R., Bollen, M., Peti, W. & Page, R. (2018). Structure, 26, 1327–1336. [DOI] [PMC free article] [PubMed]
- Bell, J. K., Mullen, G. E. D., Leifer, C. A., Mazzoni, A., Davies, D. R. & Segal, D. M. (2003). Trends Immunol. 24, 528–533. [DOI] [PubMed]
- Brautigan, D. L. & Shenolikar, S. (2018). Annu. Rev. Biochem. 87, 921–964. [DOI] [PubMed]
- Ceulemans, H., Vulsteke, V., De Maeyer, M., Tatchell, K., Stalmans, W. & Bollen, M. (2002). J. Biol. Chem. 277, 47331–47337. [DOI] [PubMed]
- Choy, M. S., Hieke, M., Kumar, G. S., Lewis, G. R., Gonzalez-DeWhitt, K. R., Kessler, R. P., Stein, B. J., Hessenberger, M., Nairn, A. C., Peti, W. & Page, R. (2014). Proc. Natl Acad. Sci. USA, 111, 4097–4102. [DOI] [PMC free article] [PubMed]
- Choy, M. S., Yusoff, P., Lee, I. C., Newton, J. C., Goh, C. W., Page, R., Shenolikar, S. & Peti, W. (2015). Cell. Rep. 11, 1885–1891. [DOI] [PMC free article] [PubMed]
- Cohen, P. T. W. (2002). J. Cell Sci. 115, 241–256. [DOI] [PubMed]
- Dall, E. & Brandstetter, H. (2013). Proc. Natl Acad. Sci. USA, 110, 10940–10945. [DOI] [PMC free article] [PubMed]
- Egloff, M. P., Johnson, D. F., Moorhead, G., Cohen, P. T., Cohen, P. & Barford, D. (1997). EMBO J. 16, 1876–1887. [DOI] [PMC free article] [PubMed]
- Eiteneuer, A., Seiler, J., Weith, M., Beullens, M., Lesage, B., Krenn, V., Musacchio, A., Bollen, M. & Meyer, H. (2014). EMBO J. 33, 2704–2720. [DOI] [PMC free article] [PubMed]
- Evans, P. R. & Murshudov, G. N. (2013). Acta Cryst. D69, 1204–1214. [DOI] [PMC free article] [PubMed]
- Finn, R. D., Clements, J. & Eddy, S. R. (2011). Nucleic Acids Res. 39, W29–W37. [DOI] [PMC free article] [PubMed]
- Gonzolez, A. & Tsai, Y. (2010). AUTOXDS. http://smb.slac.stanford.edu/facilities/software/xds/#autoxds_script.
- Hurley, T. D., Yang, J., Zhang, L., Goodwin, K. D., Zou, Q., Cortese, M., Dunker, A. K. & DePaoli-Roach, A. A. (2007). J. Biol. Chem. 282, 28874–28883. [DOI] [PubMed]
- Kabsch, W. (2010). Acta Cryst. D66, 125–132. [DOI] [PMC free article] [PubMed]
- Kumar, G. S., Gokhan, E., De Munter, S., Bollen, M., Vagnarelli, P., Peti, W. & Page, R. (2016). Elife, 5, e16539. [DOI] [PMC free article] [PubMed]
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
- O’Connell, N., Nichols, S. R., Heroes, E., Beullens, M., Bollen, M., Peti, W. & Page, R. (2012). Structure, 20, 1746–1756. [DOI] [PMC free article] [PubMed]
- Ohkura, H. & Yanagida, M. (1991). Cell, 64, 149–157. [DOI] [PubMed]
- Pedelini, L., Marquina, M., Ariño, J., Casamayor, A., Sanz, L., Bollen, M., Sanz, P. & Garcia-Gimeno, M. A. (2007). J. Biol. Chem. 282, 3282–3292. [DOI] [PubMed]
- Peti, W., Nairn, A. C. & Page, R. (2013). FEBS J. 280, 596–611. [DOI] [PMC free article] [PubMed]
- Peti, W. & Page, R. (2007). Protein Expr. Purif. 51, 1–10. [DOI] [PubMed]
- Ragusa, M. J., Dancheck, B., Critton, D. A., Nairn, A. C., Page, R. & Peti, W. (2010). Nature Struct. Mol. Biol. 17, 459–464. [DOI] [PMC free article] [PubMed]
- Rämisch, S., Weininger, U., Martinsson, J., Akke, M. & André, I. (2014). Proc. Natl Acad. Sci. USA, 111, 17875–17880. [DOI] [PMC free article] [PubMed]
- Tina, K. G., Bhadra, R. & Srinivasan, N. (2007). Nucleic Acids Res. 35, W473–W476. [DOI] [PMC free article] [PubMed]
- Weith, M., Seiler, J., van den Boom, J., Kracht, M., Hülsmann, J., Primorac, I., Del Pino Garcia, J., Kaschani, F., Kaiser, M., Musacchio, A., Bollen, M. & Meyer, H. (2018). Mol. Cell, 72, 766–777. [DOI] [PubMed]
- Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., Jain, S., Lewis, S. M., Arendall, W. B., Snoeyink, J., Adams, P. D., Lovell, S. C., Richardson, J. S. & Richardson, D. C. (2018). Protein Sci. 27, 293–315. [DOI] [PMC free article] [PubMed]
- Xu, D., Jaroszewski, L., Li, Z. & Godzik, A. (2014). Bioinformatics, 30, 660–667. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.